15 Aug GenVivo
Robert Johnson, M.D., Ph.D., Chief Operating Officer
Oct. 8 | 9:45am | FLW Ballroom F
San Marino, CA
(Private)
GenVivo is a private, clinical-stage company with a patented, off-the-shelf vector platform that fights cancer by activating the patient’s own immune system targeting the breadth of the patient’s own tumor antigens. GenVivo’s proprietary platform technology is a non-replicating RNA vector delivered intravenously (or intratumorally), thereby offering significant advantages versus both other vector-based and mRNA immunotherapies. GEN2, GenVivo’s lead clinical candidate now in a US Phase 1/2 clinical trial, designed to stimulate the immune system against all patient-specific tumor antigens—thereby creating a personalizing anti-tumor effect without the time delay and expense associated with some cancer vaccines, which are limited in the number of antigens delivered. GEN-1013 harnesses a potent anti-tumor cytokine delivered via our platform, which enables local expression while avoiding the systemic toxicity associated with other IL-12 therapies. We also have an in vivo CAR-T program using our platform with an IND planned for 2026.
